Karnofsky Performance Status
"Karnofsky Performance Status" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A performance measure for rating the ability of a person to perform usual activities, evaluating a patient's progress after a therapeutic procedure, and determining a patient's suitability for therapy. It is used most commonly in the prognosis of cancer therapy, usually after chemotherapy and customarily administered before and after therapy. It was named for Dr. David A. Karnofsky, an American specialist in cancer chemotherapy.
| Descriptor ID |
D017567
|
| MeSH Number(s) |
E05.318.308.980.438.475.456.500.500 N05.715.360.300.800.438.375.364.500.500 N06.850.520.308.980.438.475.364.500.500
|
| Concept/Terms |
Karnofsky Performance Status- Karnofsky Performance Status
- Performance Status, Karnofsky
- Status, Karnofsky Performance
- Karnofsky Performance Status Scale
- Karnofsky Scale
- Scale, Karnofsky
- Karnofsky Index
- Index, Karnofsky
|
Below are MeSH descriptors whose meaning is more general than "Karnofsky Performance Status".
Below are MeSH descriptors whose meaning is more specific than "Karnofsky Performance Status".
This graph shows the total number of publications written about "Karnofsky Performance Status" by people in this website by year, and whether "Karnofsky Performance Status" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Karnofsky Performance Status" by people in Profiles.
-
Evaluation of the key geriatric assessment constructs in primary brain tumor population - a descriptive study. J Geriatr Oncol. 2022 11; 13(8):1194-1202.
-
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 09; 100:35-45.
-
The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. Tumori. 2018 Mar-Apr; 104(2):88-95.
-
Attendance of older patients with bone metastases at a multidisciplinary bone metastases clinic: an 8-year experience. Ann Palliat Med. 2017 Aug; 6(Suppl 1):S47-S51.
-
The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. J Neurooncol. 2017 Jun; 133(2):357-368.
-
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
-
A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol. 2012 Jul; 14(7):910-8.
-
Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 01; 29(31):4175-80.
-
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011 Apr 01; 29(10):1290-6.
-
Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol. 2011 Jan; 101(2):267-77.